Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Ozanimod Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 257,511Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zydus, Synthon Ink Exclusive Licensing Deal for Ozanimod Capsules
    Zydus, Synthon Ink Exclusive Licensing Deal for Ozanimod Capsules

    04 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/zydus-and-synthon-entered-into-exclusive-licensing-and-supply-agreement-for-ozanimod-capsules-generic-version-of-zeposia-for-the-us-market-302546536.html

    PR NEWSWIRE
    04 Sep 2025
    Share Share
    Synthon's Generics Ozanimod Receives Tentative Approval in US
    Synthon's Generics Ozanimod Receives Tentative Approval in US

    22 Jul 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219236

    FDA
    22 Jul 2025
    Share Share
    S1P Receptor Modulators Face Uncertain Future In Crohn’s Disease
    S1P Receptor Modulators Face Uncertain Future In Crohn’s Disease

    14 Oct 2024

    // EXPRESSPHARMA

    https://www.expresspharma.in/s1p-receptor-modulators-face-uncertain-future-in-crohns-disease-amid-trial-setbacks/

    EXPRESSPHARMA
    14 Oct 2024
    Share Share
    Long-Term Zeposia Data Show Efficacy, Safety in Multiple Sclerosis
    Long-Term Zeposia Data Show Efficacy, Safety in Multiple Sclerosis

    18 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240917429806/en

    BUSINESSWIRE
    18 Sep 2024
    Share Share
    FDA Confirms Para IV Patent Litigation for Ozanimod HCL (Zeposia) Capsules
    FDA Confirms Para IV Patent Litigation for Ozanimod HCL (Zeposia) Capsules

    05 Jun 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-litigation-for-ozanimod-hcl-zeposia-capsules-92708.pdf

    FDA
    05 Jun 2024
    Share Share
    Bristol Myers' bowel disease drug fails in late-stage study
    Bristol Myers' bowel disease drug fails in late-stage study

    29 Mar 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-bowel-disease-drug-fails-meet-main-goal-late-stage-study-2024-03-28/

    REUTERS
    29 Mar 2024
    Share Share